

STEPAN LIFESCIENCES PVT. LTD.

PLOT No. 184, SECTOR-6, IMT MANESAR, GURUGRAM, (HARYANA) 122050

QUALITY CONTROL DEPARTMENT CERTIFICATE OF ANALYSIS

(FINISHED PRODUCT)

| D 1 | | | Page 1 of 2 |
|-------------------|-------------------------------|-------------------|------------------------|
| Product Name: | LUPREST Tablets | | |
| Generic Name : | Dydrogesterone Tablets IP 10m | σ | |
| Product Code: | 561 | A. R. No. : | FPT/25/07/069 |
| Batch No.: | SHT-561-13 | | |
| Batch Size: | 30,000 Tablets | Pack Size / Type: | 1x10 Tablets |
| Mfg. Date : | | Sampled On: | 16/07/2025 |
| | 06/2025 | Sample Quantity: | 60 Tablets |
| Exp. Date: | 05/2027 | Sampled By: | Priya |
| Reference No.: | SLQC/STP/FP/007 | Mfg. Lic. No. | 886-B(H) & 1170-OSP(H) |
| Manufactured For: | NA | Date of Analysis: | |
| Manufactured By: | Stepan Lifescience Pvt. Ltd. | | 16/07/2025 |
| Dy. | brepair Effectence PVI. Ltd. | Release Date: | 21/07/2025 |

| S.No. | | SPECIFICATION | RESULTS |
|-------|----------------------------------|--|--|
| 1. | Description | White coloured round shaped, biconvex film coated tablets, plain | White coloured round shaped, biconvex film coated tablets, |
| | | on both sides. | plain on both sides. |
| 2. | Identification: | | |
| | Identification A: (By IR) | The IR spectrum of sample should be concordant with IR spectrum obtained from reference and working standard of Dydrogesterone | The IR spectrum of sample is concordant with IR spectrum obtained from reference and working standard of Dydrogesterone. |
| | Identification B: (By HPLC) | In the assay of Dydrogesterone, the principle peak in the chromatogram obtained with the test solution corresponds to the principle peak in the chromatogram obtained with the reference solution. | In the assay of Dydrogesterone, the principle peak in the chromatogram obtained with the test solution corresponds to the principle peak in the chromatogram obtained with the reference solution. |
| 3. | Average Weight | 183.0mg | 185.1mg |
| 4. | Uniformity of Weight | 185.1mg ± 7.5 % of the average weight | Max: +3.03 % Min: -2.05% |
| 5. | Thickness | Mean: 3.54mm ± 0.2 mm | Max: 3.58mm Min: 3.52mm |
| 6. | Dissolution (BY UV) | NLT: 85%. | Min: 95.66% Max:98.44, Average=96.77% |
| 7. | Uniformity of Content: (By HPLC) | NLT: 85.0% and NMT: 115.0% | Min: 101.41% Max: 103.29%, Average=101.96% |

| Analyzed By | Checked By | | Approved By | |
|-------------------|---------------|--------|---------------|-----------|
| Officer/Executive | Head QC | A Cons | Head QA | (100) 702 |
| (Sign & Date) | (Sign & Date) | 71104 | (Sign & Date) | 21/011 |

FORMAT No.: SLQC/SOP/010/F01/R-02



STEPAN LIFESCIENCES PVT. LTD.

PLOT No. 184, SECTOR-6, IMT MANESAR, GURUGRAM, (HARYANA) 122050

QUALITY CONTROL DEPARTMENT CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

Page 2 of 2

| | | | 1 age 2 01 2 |
|----------------------|--------------------------------|-------------------|------------------------|
| Product Name: | LUPREST Tablets | | |
| Generic Name: | Dydrogesterone Tablets IP 10mg | | |
| Product Code: | 561 | A. R. No. : | FPT/25/07/069 |
| Batch No.: | SHT-561-13 | Pack Size / Type: | 1x10 Tablets |
| Batch Size: | 30,000 Tablets | Sampled On: | 16/07/2025 |
| Mfg. Date: | 06/2025 | Sample Quantity: | 60 Tablets |
| Exp. Date: | 05/2027 | Sampled By: | Priya |
| Reference No.: | SLQC/STP/FP/007 | Mfg. Lic. No. | 886-B(H) & 1170-OSP(H) |
| Manufactured For: | NA | Date of Analysis: | 16/07/2025 |
| Manufactured By: | Stepan Lifescience Pvt. Ltd. | Release Date: | 21/07/2025 |

| 8. | Related Substances: (By HPLC) | Any Other Impurities, NMT: 0.5 % Total Impurities, NMT: 1.0 % | Not Detected Not Detected |
|----|---|---|---------------------------|
| 9. | Assay: (By HPLC) Each Dydrogesterone IP 10 mg | Film coated tablet contains: NLT: 9.25 mg to NMT: 10.75 mg (92.5% to 107.5%) | 9.91mg 99.10% |

| 10. | Mic | Microbial Contamination: | | | | |
|-----|---------------------------|--------------------------|--------------------------|----------|--|--|
| | (i) Total Bacterial Count | | Not more than 1000 cfu/g | 75 cfu/g | | |
| | (ii) | Total Fungal Count | Not more than 100 cfu/g | Nil | | |
| | (ii) | (ii) Pathogen: | | | | |
| | | E. coli | Should be absent /g | Absent | | |
| | | Salmonella | Should be absent /10g | Absent | | |
| | | Staphylococcus aureus | Should be absent /g | Absent | | |
| | | Pseudomonas aeruginosa | Should be absent /g | Absent | | |
| | | Shigella | Should be absent /10g | Absent | | |

CONCLUSION: The Finish Product complies /does not complies as per IP/BP/USP/IH Specification.

Analyzed By

Checked By

Approved By

Officer/Executive (1)

Head QC

Head QA

(Sign & Date)

(Sign & Date)

(Sign & Date)

FORMAT No.: SLQC/SOP/010/F01/R-02